BE899635A - Compositions pharmaceutiques. - Google Patents

Compositions pharmaceutiques.

Info

Publication number
BE899635A
BE899635A BE0/212913A BE212913A BE899635A BE 899635 A BE899635 A BE 899635A BE 0/212913 A BE0/212913 A BE 0/212913A BE 212913 A BE212913 A BE 212913A BE 899635 A BE899635 A BE 899635A
Authority
BE
Belgium
Prior art keywords
pharmaceutical compositions
aqueous compositions
ranitidine
syrup
injections
Prior art date
Application number
BE0/212913A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10542680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE899635(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BE899635A publication Critical patent/BE899635A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention a pour objet des compositions aqueuses de ranitidine et/ou d'un ou plusieurs de ses sels physiologiquement acceptables. On constate que la durée de conservation est nettement prolongée lorsqu'on règle le pH de la composition entre 6,5 et 7,5. Compositions aqueuses appropriées pour injections, par administration intraveineuse ou intramusculaire, par perfusions continues ou par voie orale sous forme d'un sirop, dans le cadre d'un traitement anti-histaminique.
BE0/212913A 1983-05-13 1984-05-11 Compositions pharmaceutiques. BE899635A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838313217A GB8313217D0 (en) 1983-05-13 1983-05-13 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BE899635A true BE899635A (fr) 1984-11-12

Family

ID=10542680

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/212913A BE899635A (fr) 1983-05-13 1984-05-11 Compositions pharmaceutiques.

Country Status (20)

Country Link
US (1) US4585790A (fr)
JP (1) JPH0639378B2 (fr)
AU (1) AU568647B2 (fr)
BE (1) BE899635A (fr)
CA (1) CA1216240A (fr)
CH (1) CH662272A5 (fr)
CZ (1) CZ281598B6 (fr)
DE (1) DE3417606C2 (fr)
DK (1) DK165663B (fr)
FR (1) FR2547727B1 (fr)
GB (2) GB8313217D0 (fr)
IE (1) IE57397B1 (fr)
IL (1) IL71813A (fr)
IT (1) IT1179367B (fr)
NL (1) NL194429C (fr)
NZ (1) NZ208127A (fr)
PH (1) PH20574A (fr)
SE (1) SE459898B (fr)
SK (1) SK279526B6 (fr)
ZA (1) ZA843584B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
GB8927503D0 (en) * 1989-12-04 1990-02-07 Kronem Systems Inc Enzyme-amplified lanthanide chelate luminescence
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
WO1995010274A1 (fr) * 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Composition pharmaceutique aqueuse
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations
GB9715423D0 (en) * 1997-07-23 1997-09-24 Glaxo Group Ltd Aqueous compositions
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2001056547A2 (fr) * 2000-02-04 2001-08-09 Seo Hong Yoo Preparation de formes posologiques a base de solutions aqueuse claires a partir d'acides biliaires
KR100412290B1 (ko) * 2001-11-27 2003-12-31 주식회사 동구제약 라니티딘 함유 현탁제 조성물 및 그의 제조방법
WO2003055483A1 (fr) * 2001-12-27 2003-07-10 Terumo Kabushiki Kaisha Solution d'injection de famotidine
JP2006008696A (ja) * 2003-03-20 2006-01-12 Mitsubishi Pharma Corp アルギニンアミド類を含有する医薬製剤
US7145125B2 (en) * 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (fr) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Utilisation des inhibiteurs de PDE III pour la réduction de la taille du coeur chez des mammifères souffrant d'insufficances cardiaques
JP2008511651A (ja) * 2004-08-30 2008-04-17 セオ ホン ユー 局所虚血モデルでの可溶化ｕｄｃａの神経保護効果
BRPI0518191A (pt) * 2004-10-15 2008-11-04 Seo Hong Yoo métodos e composições para reduzir a toxicidade de um composto farmacêutico
CA2585471A1 (fr) * 2004-11-01 2006-05-11 Seo Hong Yoo Procedes et compositions de reduction de la neurodegeneration dans la sclerose laterale amyotrophique
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
JP2006271748A (ja) * 2005-03-30 2006-10-12 Taiyo Yakuhin Kogyo Kk 変質しない注射剤包装
WO2007022105A2 (fr) * 2005-08-12 2007-02-22 Rubicon Research Pvt. Ltd. Préparations pharmaceutiques stables, procédés de fabrication desdites préparations et méthodes d'emploi
WO2008039792A1 (fr) * 2006-09-25 2008-04-03 Scidose Llc Compositions pharmaceutiques stables d'une formulation préservée de ranitidine, procédé de fabrication et procédé d'utilisation
EP1920785A1 (fr) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Préparation liquide contenant un complexe du pimobendane et de la cyclodextrine
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
CN113181110A (zh) 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
EP3106150B1 (fr) 2013-12-04 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Compositions pharmaceutiques améliorées de pimobendane
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3626054A (en) * 1967-10-25 1971-12-07 Bard Hamilton Co Inc Lupus erythematosus skin test
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4203909A (en) * 1978-09-26 1980-05-20 Bristol-Myers Company Furan compounds
DE3108753A1 (de) * 1981-03-07 1982-09-16 Degussa Ag, 6000 Frankfurt Neue substituierte alkyl-phenylsulfonylguanidine miteinem heterocyclischen rest

Also Published As

Publication number Publication date
ZA843584B (en) 1985-12-24
GB8412108D0 (en) 1984-06-20
GB2142820B (en) 1987-01-14
NL194429C (nl) 2002-04-04
IL71813A (en) 1988-03-31
AU568647B2 (en) 1988-01-07
IT1179367B (it) 1987-09-16
CA1216240A (fr) 1987-01-06
DE3417606A1 (de) 1984-11-15
IE841179L (en) 1984-11-13
GB8313217D0 (en) 1983-06-22
DK165663B (da) 1993-01-04
SE459898B (sv) 1989-08-21
CH662272A5 (fr) 1987-09-30
FR2547727A1 (fr) 1984-12-28
JPH0639378B2 (ja) 1994-05-25
GB2142820A (en) 1985-01-30
IE57397B1 (en) 1992-08-26
FR2547727B1 (fr) 1988-02-26
DE3417606C2 (de) 1996-03-14
DK237884D0 (da) 1984-05-11
DK237884A (da) 1984-11-14
NZ208127A (en) 1987-05-29
CS403691A3 (en) 1992-08-12
SE8402560D0 (sv) 1984-05-11
NL194429B (nl) 2001-12-03
PH20574A (en) 1987-02-18
IT8448182A0 (it) 1984-05-11
JPS59219225A (ja) 1984-12-10
US4585790A (en) 1986-04-29
CZ281598B6 (cs) 1996-11-13
AU2792984A (en) 1984-11-15
SK279526B6 (sk) 1998-12-02
NL8401524A (nl) 1984-12-03
SE8402560L (sv) 1984-11-14
IL71813A0 (en) 1984-09-30

Similar Documents

Publication Publication Date Title
BE899635A (fr) Compositions pharmaceutiques.
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
DE69100991D1 (de) Pharmazeutische formulierungen.
KR920002144A (ko) 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제
TNSN98090A1 (fr) Formulations pharmaceutiques contenant du voriconazole, et procede pour leur preparation.
DE69720759D1 (de) Gut schmeckende, fluessige, waessrige zusammensetzung fuer ein bitterschmeckendes arzneimittel
ES2058111T3 (es) Composicion de liberacion controlada de dihidrocodeina.
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
ATE213940T1 (de) Parenteral anzuwendende arzneizubereitung enthaltend amiodaron
IT1282353B1 (it) Composizione farmaceutica, in particolare liquida, per sommanistrazione orale di ondansetron e metodi per la sua produzione
FR2712807B1 (fr) Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale .
EP0375628A3 (fr) Utilisation de l'acétyle-L-carnitine pour le traitement de la cataracte et compositions pharmaceutiques utilisables pour ce traitement
DK0615442T3 (da) Solreguleret termokolloidmatrix på gelatinebasis til perorale former med retarderet frigivelse.
KR970025615A (ko) 암 전이 억제제
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
EE200100066A (et) Naatriumkloriidi kasutamine kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsetekõrvaltoimete vähendamiseks
MA26788A1 (fr) COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION
PT1058544E (pt) Inibicao da actividade do tnf
KR880004810A (ko) 소화성 궤양 치료제
PT711163E (pt) Utilizacao de benzidamina no tratamento de estados patologicos provocados por tnf
FR2507084B1 (fr) Composition antibiotique pour l'administration de la phosphomycine sous forme de comprimes a dissolution lente
CA2069202A1 (fr) Utilisation de 1-(5-oxohexyl)-3-methyl-7-n-propylxanthine en chirurgie vasculaire

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *GLAXO GROUP LTD

Effective date: 20040511